AngioDynamics Announces FDA Clearance for Celerity Tip Location System

ALBANY, N.Y., June 18, 2014 -- AngioDynamics (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Celerity tip location system.

The Celerity System has been cleared by the FDA as an adjunct to aid in positioning Peripherally Inserted Central Catheters (PICCs) in adults by providing real time catheter tip location utilizing the patient's cardiac electrical activity. The Company expects to begin U.S. distribution in early July. In March, AngioDynamics announced an agreement to acquire regulatory control over the Celerity platform from the Company's business partner, Medcomp, and its development partner, after the FDA rejected Medcomp's initial 510(k) application.

Medtronic to Acquire Covidien for $42.9 billion in Cash and Stock

Creates a Medical Technology and Services Company with a Comprehensive Product Portfolio and Broad Global Reach that is Better Able to Improve Healthcare Outcomes --- Meaningfully Accelerates Medtronic's Core Strategies of Therapy Innovation, Globalization and Economic Value --- Combined Revenue of $27 Billion, including $3.7 Billion from Emerging Markets --- Transaction Expected to be Accretive to Medtronic Cash Earnings in FY2016 and Significantly Accretive thereafter --- Medtronic Commits to $10 Billion in Additional U.S. Technology Investments Over 10 Years

MINNEAPOLIS AND DUBLIN - June 15, 2014 - Medtronic, Inc. (NYSE: MDT), a global leader in medical technology, services and solutions, and Covidien plc (NYSE: COV), a global healthcare technology and medical supplies provider, today announced that they have entered into a definitive agreement under which Medtronic has agreed to acquire Covidien in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion, based on Medtronic's closing stock price of $60.70 per share on June 13, 2014.

Luminex Corporation Reports First Quarter 2014 Results

AUSTIN, Texas, April 28, 2014 -- Luminex Corporation (LMNX) today announced financial results for the first quarter ended March 31, 2014.  Financial and operating highlights include the following:

• Consolidated first quarter revenues reached $56.6 million, a 6 percent increase over the first quarter of 2013
• Consolidated gross profit margin was 71 percent for the first quarter of 2014
• First quarter assay revenue of $21.7 million, an 18 percent increase over the first quarter of 2013. Infectious disease sales comprised approximately 65 percent of total assay revenue, with genetic testing representing 35 percent.
• First quarter consumable sales of $12.8 million, a 7 percent increase over the first quarter of 2013